Understanding the STEP-BD Study
The Carlat Psychiatry Report, Volume 4, Number 8, August 2006
Gary S. Sachs, MD
Associate Professor of Psychiatry, Harvard Medical School
Director, Bipolar Clinic and Research Program, Massachusetts General Hospital, Boston, Massachusetts
Dr. Sachs has disclosed that he is the recipient of research grants from Abbott, GlaxoSmithKline, Janssen, Repligen, Pfizer, and Wyeth; is a consultant for Abbott, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Janssen, JDS, Memory, Repligen, Pfizer, Solvay, and Wyeth; and is a member of the speakers bureaus of Abbott, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, and Eli Lilly. The editors of The Carlat Psychiatry Report have reviewed the content of Dr. Goddard’s interview and have resolved any financial conflicts of interest regarding this educational activity. The author has disclosed that inositol has not been approved by the U.S. Food and Drug Administration for use in the treatment of bipolar disorder.
Dr. Sachs, as the principal investigator of the STEP-BD study, can you walk us through how the study was hatched?